Manitoba Institute of Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Manitoba, Canada.
Manitoba Institute of Cell Biology, University of Manitoba, CancerCare Manitoba, Winnipeg, Manitoba, Canada ; Département de Biochimie, Faculté de Médecine et des Sciences de la Santé, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Transl Oncol. 2013 Dec 1;6(6):749-56. doi: 10.1593/tlo.13613.
Multiple myeloma (MM) is preceded by monoclonal gammopathy of undetermined significance (MGUS). Up to date, it is difficult to predict an individual's time to disease progression and the treatment response. To examine whether the nuclear telomeric architecture will unravel some of these questions, we carried out. Three-dimensional (3D) telomere analysis on samples from patients diagnosed with MGUS and MM, as well as from patients who went into relapse. Telomere signal intensity, number of telomere aggregates, nuclear volume, and the overall nuclear telomere distribution (a/c ratio) were analyzed. The telomeric profiles allowed for the differentiation of the disease stages. The telomeric profiles of myeloma cells obtained from blood and bone marrow aspirates were identical. Based on this study, we discuss the use of 3D telomere profiling as a potential future tool for risk stratification and personalized treatment decisions.
多发性骨髓瘤(MM)之前是意义未明的单克隆丙种球蛋白血症(MGUS)。迄今为止,很难预测个体的疾病进展时间和治疗反应。为了研究核端粒结构是否能解决其中的一些问题,我们进行了研究。对诊断为 MGUS 和 MM 以及复发的患者的样本进行了三维(3D)端粒分析。分析了端粒信号强度、端粒聚集数、核体积和整体核端粒分布(a/c 比)。端粒谱可区分疾病阶段。从血液和骨髓抽吸物获得的骨髓瘤细胞的端粒谱是相同的。基于这项研究,我们讨论了使用 3D 端粒分析作为一种潜在的风险分层和个性化治疗决策的未来工具。